Vedolizumab has been found to have unusual gut selectivity features in clinical studies, and these properties may help explain why the drug has a favourable benefit-risk profile. In this review, we present data onClinical Manifestation, Application Treatment pattern and Safety Analysis of Vedolizumab. A recurrent and remitting clinical history, chronic inflammation, the requirement for lifelong medication, and usually significant morbidity are the hallmarks of Crohn's disease (CD), ulcerative colitis (UC), and other inflammatory bowel disorders (IBD).